About | Free Trial

Last Update

2015-10-08T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Harry Wilcox?

Mr. Harry Wilcox W. III

Senior Vice President Corporate Development

EXACT Sciences Corporation

Direct Phone: (508) ***-****       

EXACT Sciences Corporation

441 Charmany Drive

Madison, Wisconsin 53719

United States

Company Description

EXACT Sciences Corporation develops deoxyribonucleic acid (DNA)-based technologies for use in the detection of cancer. The Company has selected colorectal cancer as the first application of its technologies. The Company has licensed certain of its technol ... more

Find other employees at this company (491)

Background Information

Employment History

Board Member
T2 Biosystems, Inc.

Chief Financial Officer and Partner
Flagship Ventures

Chief Executive Officer and President
Cambridge NeuroScience , Inc.

Education

BS
finance
University of Arizona

M.B.A.

Boston University

MBA

Boston University School of Management

Web References (167 Total References)


Harry Wilcox | Flagship Ventures

www.flagshipventures.com [cached]

Home > About > Flagship Team > Harry Wilcox

...
Harry Wilcox
...
Harry Wilcox
...
Harry Wilcox Chief Operating Officer and General Partner
Harry joined Flagship Ventures in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. His career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has also served on several Boards of Directors. In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures.
Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences (NASDAQ:EXAS), one of Flagship's portfolio companies. In addition to EXACT Sciences, Harry led an active consulting practice which included roles as interim CEO of two biotech companies: Thrasos Therapeutics and Biostratum. Prior to this, Harry was Executive Vice President, Chief of Finance and Corporate Development of Pyrosequencing, a publicly-held European biotech company. Earlier, he had been the President and Chief Executive Officer of Cambridge NeuroScience, Inc. (NASDAQ:CNSI) until its sale to CeNeS Pharmaceuticals, and before that Sr. VP Business Development and CFO of Cellcor.
As COO and General Partner at Flagship Ventures, Harry is responsible for the operational management of Flagship's VentureLabsTM unit, serves as a member of Flagship's investment committee, and oversees the firm's financial operations and LP relations/fundraising. He was a board member of Accuri Cytometers prior to its successful sale to Becton Dickinson. He also plays a role as board member or advisor to select portfolio companies and is currently a board member of BG Medicine, Celexion, Quantum Designs, Seahorse Bioscience, Selventa, Seventh Sense Biosystems, Tangent Medical Technologies, Inc. and T2 Biosystems.


About Us | IV Catheter, IV TherapyTangent Medical

tangentmedical.com [cached]

Harry Wilcox Chief Operating Officer and General Partner, Flagship Ventures

Harry Wilcox brings a rich set of experiences and expertise in financial management, operations, fund management and strategy to the Tangent Medical Board of Directors. As COO and General Partner at Flagship Ventures, Harry oversees the firm's financial operations and LP relations/fundraising, and serves as board member or advisor to select portfolio companies. Harry is currently a board member of Black Duck, Celexion, Seahorse Bioscience, Seventh Sense Biosystems and T2 Biosystems.
Harry's career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has also served on several Boards of Directors. Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences (NASDAQ:EXAS), one of Flagship's portfolio companies, and on the Board of another portfolio company, Epitome Biosystems.
In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures. Harry has also led an active consulting practice, which included roles as interim CEO of biotech companies Thrasos Therapeutics and Biostratum.


Celexion Team

www.celexionbio.com [cached]

Harry Wilcox Director

Harry is currently Chief Financial Officer and Partner, Flagship Ventures, and brings to Celexion a rich set of experiences and expertise in financial management, operations, fund management and strategy. Harry joined Flagship Ventures in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. His career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has also served on several Boards of Directors. In addition to his corporate experience, Harry was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures.
Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences (NASDAQ:EXAS), one of Flagship's portfolio companies. In addition to EXACT Sciences, Harry led an active consulting practice which included roles as interim CEO of two biotech companies: Thrasos Therapeutics and Biostratum. Prior to this, Harry was Executive Vice President, Chief of Finance and Corporate Development of Pyrosequencing, a publicly-held European biotech company. Earlier, he had been the President and Chief Executive Officer of Cambridge NeuroScience, Inc. (NASDAQ:CNSI) until its sale to CeNeS Pharmaceuticals, and before that Sr. VP Business Development and CFO of Cellcor.
As COO and General Partner at Flagship Ventures, Harry is responsible for the operational management of Flagship's VentureLabsTM unit, serves as a member of Flagship's investment committee, and oversees the firm's financial operations and LP relations/fundraising. He was a board member of Accuri Cytometers prior to its successful sale to Becton Dickinson. He also plays a role as board member or advisor to select portfolio companies and is currently a board member of Black Duck, Celexion, Quantum Designs, Seahorse Bioscience, Selventa, Seventh Sense Biosystems, Tangent Medical Technologies, Inc. and T2 Biosystems.


Seventh Sense Biosystems :: Company

www.7sbio.com [cached]

Harry Wilcox - Chief Operating Officer and General Partner, Flagship Ventures

Mr. Wilcox joined Flagship Ventures in 2006, bringing a rich set of experiences and expertise in financial management, operations, fund management and strategy. As COO and General Partner at Flagship Ventures, Mr. Wilcox oversees the firm's financial operations and LP relations/fundraising, and serves as board member or advisor to select portfolio companies. Mr. Wilcox is currently a board member of Black Duck, Celexion, Seahorse Bioscience, T2 Biosystems and Tangent Medical.
Mr. Wilcox's career spans 30 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has also served on several Boards of Directors. Most recently he has served as CFO and then Sr. VP Corporate Development for EXACT Sciences (NASDAQ:EXAS), one of Flagship's portfolio companies, and on the Board of another portfolio company, Epitome Biosystems.
In addition to his corporate experience, Mr. Wilcox was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures. Mr. Wilcox has also led an active consulting practice, which included roles as interim CEO of biotech companies Thrasos Therapeutics and Biostratum. Mr. Wilcox earned a BS in finance from the University of Arizona and an MBA from Boston University School of Management.


Board of Directors | About | T2Biosystems

www.t2biosystems.com [cached]

Harry Wilcox

COO and General Partner, Flagship Ventures
Harry W. Wilcox has served as a member of our board of directors since January 2011. Harry has been Chief Operating Officer and General Partner of Flagship Ventures, a venture capital firm, since 2013. From 2006 to 2013, he was Chief Financial Officer and Partner of Flagship Ventures. From 2004 to 2006, he was Chief Financial Officer and Senior Vice President of Corporate Development of EXACT Sciences. Harry received his M.B.A. from Boston University and his B.S. in Finance from the University of Arizona.

Similar Profiles

Other People with this Name

Other people with the name Wilcox

Debra Wilcox
Christian Children's Home

Nick Wilcox
I3 Business Solutions , LLC

Jonathan Wilcox

Trevor Wilcox
LeMatic , Inc.

Brian Wilcox
Northeast Bradford School District

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory